Crystal form of N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide
AssigneeAventis Pharma Deutschland GmbH
InventorsHolger Faasch, Udo Hedtmann, Uwe Westenfelder, Erich Paulus
Life of this patent
Estimating the term…
Loading patent…
AssigneeAventis Pharma Deutschland GmbH
InventorsHolger Faasch, Udo Hedtmann, Uwe Westenfelder, Erich Paulus
Estimating the term…
The invention relates to a crystal modification of the compound of the formula I and the processes for the preparation of and use that crystal modifications 1. The invention is used for treating acute immunological episodes, such as sepsis, allergies, graft-versus-host and host-versus-graft-reactions, autoimmune diseases, in particular rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, psoriasis, atopic dermatitis, asthma, urticaria, rhinitis, uveitis, type 11 diabetes, liver fibrosis, cystic fibrosis, colitis, cancers, such as lung cancer, leukemia, ovarian cancer, sarcomas, Kaposi's sarcoma, meningioma, intestinal cancer, lymphatic cancer, brain tumors, breast cancer, pancreatic cancer, prostate cancer, or skin cancer.
A method for detecting a first crystal modification of a compound of formula (I)
A method for quantifying the amount of a first crystal modification of a compound of formula (I)
Dependencies are inferred from the claim text.